MedPath

Eribulin

Generic Name
Eribulin
Brand Names
Halaven, Eribulin Baxter, Mevlyq
Drug Type
Small Molecule
Chemical Formula
C40H59NO11
CAS Number
253128-41-5
Unique Ingredient Identifier
LR24G6354G
Background

Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .

Indication

For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.

Associated Conditions
Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
Clinical Trials
Related News

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Phase 2
Active, not recruiting
Conditions
Stage IV Breast Inflammatory Carcinoma
Recurrent Breast Inflammatory Carcinoma
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
First Posted Date
2017-06-28
Last Posted Date
2025-04-02
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
35
Registration Number
NCT03202316
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas

Completed
Conditions
Sarcoma, Soft Tissue
Interventions
First Posted Date
2017-02-20
Last Posted Date
2020-04-06
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
256
Registration Number
NCT03058406

A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2017-02-14
Last Posted Date
2024-03-06
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
90
Registration Number
NCT03051659
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Phase 2
Withdrawn
Conditions
BRCA1 Mutation
Breast Cancer Stage IV
Ovarian Cancer
BRCA2 Mutation
Interventions
First Posted Date
2017-01-26
Last Posted Date
2017-10-10
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Registration Number
NCT03032614

Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy

Completed
Conditions
Locally Advanced or Metastatic Breast Cancer
Interventions
First Posted Date
2017-01-23
Last Posted Date
2022-07-13
Lead Sponsor
Eisai GmbH
Target Recruit Count
353
Registration Number
NCT03027245
Locations
🇩🇪

Eisai Trial Site 2, Stuttgart, Germany

🇩🇪

Eisai Trial Site 3, Munchen, Germany

🇩🇪

EISAI Trial Site 1, Dresden, Germany

and more 1 locations

To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors

Phase 1
Completed
Conditions
Tumor
Interventions
First Posted Date
2016-12-23
Last Posted Date
2017-03-15
Lead Sponsor
Eisai Limited
Target Recruit Count
14
Registration Number
NCT03002493
Locations
🇳🇱

Netherlands Cancer Institute, Amsterdam, Netherlands

🇳🇱

University Medical Center Utrecht, Utrecht, Netherlands

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

First Posted Date
2016-09-27
Last Posted Date
2023-04-14
Lead Sponsor
Nektar Therapeutics
Target Recruit Count
178
Registration Number
NCT02915744
Locations
🇺🇸

Investigator Site - Plantation, Plantation, Florida, United States

🇺🇸

Investigator Site - Boston, Boston, Massachusetts, United States

🇺🇸

Investigator Site - Columbus, Columbus, Ohio, United States

and more 50 locations

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

Phase 4
Completed
Conditions
Toxicity
Adverse Drug Event
Neurotoxicity
Drug Toxicity
Metastatic Breast Cancer
Interventions
First Posted Date
2016-08-11
Last Posted Date
2021-03-04
Lead Sponsor
Oncologia Medica dell'Ospedale Fatebenefratelli
Target Recruit Count
200
Registration Number
NCT02864030
Locations
🇮🇹

Comprensorio sanitario di Bolzano, Bolzano, Italy

🇮🇹

Istituti Ospitalieri di Cremona, Cremona, Italy

🇮🇹

A.O.U. Careggi, Firenze, Italy

and more 17 locations

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

Phase 1
Terminated
Conditions
Breast Cancer
Breast Adenocarcinoma
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Recurrent Breast Carcinoma
Stage IV Breast Cancer
Interventions
First Posted Date
2016-07-06
Last Posted Date
2022-04-04
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
28
Registration Number
NCT02824575
Locations
🇺🇸

Montefiore Medical Center, Bronx, New York, United States

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Phase 1
Terminated
Conditions
Metastatic Breast Cancer
Interventions
First Posted Date
2016-04-28
Last Posted Date
2020-07-13
Lead Sponsor
Eisai Inc.
Target Recruit Count
25
Registration Number
NCT02753595
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy